SOLIGENIX, INC. 8-K

What Happened
Soligenix, Inc. (SNGX) filed an 8‑K on May 28, 2026 to disclose a prospectus supplement that increases the maximum aggregate amount of common stock issuable under its At‑Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,956,000. The company previously sold approximately $3,445,000 of common stock under the same Sales Agreement pursuant to an earlier prospectus supplement. A legal opinion regarding the legality of the additional $2,956,000 of shares is filed as Exhibit 5.1.

Key Details

• Increased ATM capacity: $2,956,000 additional shares (aggregate offering amount).
• Prior sales under the Sales Agreement: ~ $3,445,000 of common stock sold under a prior prospectus supplement.
• Sales Agreement date: January 23, 2026 (Rodman & Renshaw LLC acting as agent).
• Filing date: May 28, 2026; legal opinion filed as Exhibit 5.1.

Why It Matters
This change gives Soligenix flexibility to raise equity capital quickly by selling shares into the market under its ATM facility. If the company chooses to sell shares, those sales would dilute existing shareholders but provide near-term financing without negotiating a single large private placement. The 8‑K does not report any immediate share issuance or proceeds—only expanded capacity under the existing sales agreement.